In this short interview, Dr Ellen Apperloo (University Medical Center Groningen, Groningen, NL) discusses the key outcomes of tirzepatide in a cohort of type 2 diabetes patients from a pooled post-hoc analysis of the SURPASS 1-5 clinical trials.

Findings showed that tirzepatide was associated with reduced urine albumin-creatinine ratio (uACR) compared to all comparators, including semaglutide and insulin, suggesting a potential kidney-protective effect.

Interview Questions:

1. What led you to investigate tirzepatide's effects on albuminuria across the SURPASS program?
2. Could you walk us through your decision to conduct this particular post hoc analysis and how you determined which subgroups to examine?
3. What were the key findings of the analysis?
4. How might these findings influence treatment approaches for patients with both type 2 diabetes and early signs of kidney disease?
5. What questions about tirzepatide's kidney-protective effects remain unanswered that you'd like to explore in future studies?
6. Are there any dedicated renal outcome trials with tirzepatide currently planned or underway?

Recorded remotely from Groningen, 2025.

Editor: John Rhodes-Finney
Video Specialist: Oliver Miles